Fig. 1From: Multiple myeloma: characterization of patients through the analysis of semiquantitative parameters with 18F-FDG PETA 60-year-old man with MM diagnosis. Whole-body PET (A) performed at baseline demonstrated multiple areas of increased tracer uptake in bones, particularly evident in the left shoulder (black bordered arrow). Six months after VTD (Velcade® + Thalidomide + dexamethasone) chemotherapy, whole-body PET (B) showed almost complete metabolic response, with minimal residual tracer uptake in the right shoulder (black bordered arrow)Back to article page